Subject Expert Committee of India’s central drug authority has recommended the regular market approval to Covid-19 Vaccines – Covaxin and Covishield with conditions for the adult population. In a tweet, the Central Drugs Standard Control Organisation (CDSCO) said, the Subject Expert Committee has recommended the upgrade of Covaxin and Covishield status from restricted use in emergency situations to grant new drug permission with conditions in the adult population. It said, the Drugs Controller General of India (DCGI) will evaluate the recommendations and give its decision.
Serum Institute of India had applied for market approval for Covishield and Bharat Biotech for its Covaxin vaccine.
